Synergism between gamma interferon and doxorubicin in a human MDR colon adenocarcinoma cell line

F. Monti, E. Lalli, A. Bontadini, S. Szymczuk, E. Pini, A. Tononi, P. P. Fattori, A. Facchini, A. Ravaioli

Research output: Contribution to journalArticlepeer-review


Recent interest in cancer therapy derives from the ability of interferons to synergistically increase the activity of chemotherapeutic agents. To understand the biological basis of this synergism we evaluated the effects of human recombinant IFN-γ on the expression of the mdr1 gene and on the cellular growth of a human colon adenocarcinoma cell line (LoVo) and its MDR subline (LoVo/Dx) after coincubation with doxorubicin. Treatment with IFN-γ showed unchanged levels of MDR1-glycoprotein, no perturbation on cell cycle distribution and a significant reduction of colony formation in both lines (P <0.05) starting from 100 U/ml. A synergistic effect was observed in the LoVo/Dx cell line when doxorubicin was added after exposure to 0.1-10 U/ml of IFN-γ. Our data indicate that the effects of IFN-γ, independent from action on cell proliferation and from modulation of p-glycoprotein expression, are a cause of the synergistic activity between this lymphokine and conventional chemotherapeutic agents such as doxorubicin.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalJournal of Chemotherapy
Issue number5
Publication statusPublished - 1994


  • doxorubicin IFN-γ
  • gp1701
  • MDR colon adenocarcinoma

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)


Dive into the research topics of 'Synergism between gamma interferon and doxorubicin in a human MDR colon adenocarcinoma cell line'. Together they form a unique fingerprint.

Cite this